State-Sponsored Racism: FDA Guidelines Instruct Healthcare Providers to Prioritize Racial Minorities Over Whites For Access to Scarce Covid Treatments
In several states like New York, Minnesota, Utah, and even Texas, non-white citizens are receiving priority for scarce monoclonal antibody treatments and Covid oral antiviral pills, regardless of their age or underlying conditions, thanks to Marxist health-equity policies that have been implemented by the local governments.
This ‘rationing based on race’ policy has sparked intense backlash against the states which have implemented them, but the idea did not start within local health departments – the destructive scheme actually came directly from the Food and Drug Administration (FDA), according to the agency’s own documents.
The FDA’s emergency use authorizations for monoclonal antibodies and oral antivirals specify that the treatments have only been authorized for “high risk” patients. The agency included guidelines on what factors would qualify a patient to receive the therapeutics, and unsurprisingly, one of the main determinations was their race.
Even though the FDA’s guidelines are nonbinding and unenforceable, they have been used by the local state governments as justification for implementing the racist policy.
Racism – FDA approved – because, it’s for your health.
From The Washington Free Beacon:
The FDA “fact sheet” for Sotrovimab, the only monoclonal antibody effective against the Omicron variant, states that ‘race or ethnicity’ can ‘place individual patients at high risk for progression to severe COVID-19.’
The fact sheet for Paxlovid, Pfizer’s new antiviral pill, uses the Centers for Disease Control and Prevention’s definition of ‘high risk,‘ which states that ‘systemic health and social inequities’ have put minorities ‘at increased risk of getting sick and dying from COVID-19.’
The guidance sheets are nonbinding and do not require clinicians to racially allocate the drugs. But states have nonetheless relied on them to justify race-based triage.
“The FDA has acknowledged that in addition to certain underlying health conditions, race and ethnicity ‘may also place individual patients at high risk for progression to severe COVID-19,’ Minnesota’s plan reads. ‘FDA’s acknowledgment means that race and ethnicity alone, apart from other underlying health conditions, may be considered in determining eligibility for [monoclonal antibodies].'”
How is this even legal in America?
The FDA declined to comment on either state’s plan, saying only that “there are no limitations on the authorizations that would restrict their use in individuals based on race,” according to The Washington Free Beacon.
https://www.thegatewaypundit.com/2022/01/state-sponsored-racism-fda-guidelines-instruct-healthcare-providers-prioritize-racial-minorities-whites-access-scarce-covid-treatments/